Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05275946
Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)
Overview
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty in implementing and continuing standard treatment. The safety, pharmacokinetics, absorbed dose, and efficacy will be evaluated to determine the recommended dose for Phase II clinical trial.
Sponsor
Osaka University
Phase
Phase 1
Contacts
Tadashi Watabe, M.D., Ph.D. (Principal Investigator)
watabe@tracer.med.osaka-u.ac.jp
+81-6-6879-3461
ClinicalTrials.gov
NCT05275946Drug / Compound
Isotope(s):
ASTATINE-211
Radioisotope: At-211
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 7.2 hours
Decay Mode: ALPHA, ELECTRON CAPTURE
Energy: 2 Alpha particles 5.87 & 7.45 MeV
Range: 50-100 micrometers
Decay Daughters: Bi207, Po211
Status: Clinical Trials Only
Target(s):
Share your feedback
Help us improve your experience